Extension Study of MT-1303 in Subjects With Crohn's Disease
NCT ID: NCT02389790
Last Updated: 2017-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
46 participants
INTERVENTIONAL
2015-08-31
2017-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
-To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD）
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
NCT02378688
Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease
NCT02148185
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
NCT02531113
A Study of TRK-170 for the Treatment of Crohn's Disease
NCT01345799
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease
NCT01666327
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MT-1303
MT-1303
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MT-1303
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mitsubishi Tanabe Pharma Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigational site
City Name, , Czechia
Investigational site
City Name, , France
Investigational site
City Nmae, , Germany
Investigational site
City Nmae, , Hungary
Investigational site
City Name, , Israel
Investigational site
City Name, , Italy
Investigational site
City Nmae, , Japan
Investigational site
City Name, , Netherlands
Investigational site
City Name, , Poland
Investigational site
City Name, , Slovakia
Investigational site
City Name, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT-1303-E14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.